Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate  by Rothstein, Jeffrey D et al.
Neuron, Vol. 16, 675±686, March, 1996, Copyright 1996 by Cell Press
Knockout of Glutamate Transporters Reveals
a Major Role for Astroglial Transport
in Excitotoxicity and Clearance of Glutamate
Jeffrey D. Rothstein,* Margaret Dykes-Hoberg,* (Arriza et al., 1994). The localization of these transporters
has revealed that EAAC1 is selectively localized to neu-Carlos A. Pardo,² Lynn A. Bristol,* Lin Jin,*
Ralph W. Kuncl,* Yoshikatsu Kanai,³ rons (Rothstein et al., 1994, 1995), whereas GLT-1
(Rothstein et al., 1994, 1995; Lehre et al., 1995) andMatthias A. Hediger,§ Yanfeng Wang,‖
Jerry P. Schielke,# and Devin F. Welty‖ GLAST (Rothstein et al., 1994, 1995; Lehre et al., 1995)
are astroglial transporters. The relative contribution of*Department of Neurology
²Department of Neuropathology each of these transporters to the synaptic clearance of
glutamate is not known. It has been suggested thatJohns Hopkins University
Baltimore, Maryland 21287 under certain pathophysiological circumstances, such
as acute cerebral ischemia and epilepsy, glutamate³Department of Pharmacology
Kyorin University School of Medicine neurotoxicity is propagated due to failure or reversal
of glutamate transport (Nicholls and Attwell, 1990;6-20-2 Shinkawa Mitaka
Tokyo, 181 Rothstein et al., 1992; Attwell et al., 1993; Kanai and
Hediger, 1995; Kanai et al., 1995b). Furthermore, a sub-Japan
§Department of Medicine stantial loss of the glial glutamate transporter, GLT-1,
has been demonstrated in the chronic degenerative dis-Renal Division
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From these experiments, we have gathered biochemicalAnn Arbor, Michigan 48105
and morphological data that suggest that in the spinal
cord, striatum, and hippocampus astroglial transporters
GLT-1 and GLAST, but not the neuronal transporterSummary
EAAC1, are responsible for chronic glutamate-mediated
neurotoxicity.Three glutamate transporters have been identified in
rat, including astroglial transporters GLAST and GLT-1
and a neuronal transporter EAAC1. Here we demon- Results
strate that inhibition of the synthesis ofeach glutamate
transporter subtype using chronic antisense oligonu- Organotypic Spinal Cord Cultures
cleotide administration, in vitro and in vivo, selectively In the first set of studies, antisense oligonucleotides to
and specifically reduced the protein expression and GLT-1, GLAST, or EAAC1 were individually added to
function of glutamate transporters. The loss of glial spinal cord organotypic cultures (Rothstein et al., 1993).
glutamate transporters GLAST or GLT-1 produced ele- These cultures were used because they have the advan-
vated extracellular glutamate levels, neurodegenera- tage of maintaining the normal synaptic morphology,
tion characteristic of excitotoxicity, and a progressive including astroglial/neuronal interactions, and have a
paralysis. The loss of the neuronal glutamate trans- stable population of motor neurons that can be studied
porter EAAC1 did not elevate extracellular glutamate for over two months (Rothstein et al., 1993). In addition,
in the striatum but did produce mild neurotoxicity and they afforded a relatively rapid, inexpensive method to
resulted in epilepsy. These studies suggest that glial screen various antisense sequences. Culture medium,
glutamate transporters provide the majority of func- including oligonucleotides and added drugs, was
tional glutamate transport and are essential for main- changed twice weekly. All experiments were performed
taining low extracellular glutamate and for preventing with phosphorothioate oligonucleotides. One week after
chronic glutamate neurotoxicity. preparation of cultures, sense or antisense oligonucleo-
tides (5 mM) were added to cultures. Antisense oligonu-
cleotides to GLAST and GLT-1 decreased levels ofIntroduction
GLAST by 88% 6 2% (SEM; n 5 5) and GLT-1 by
67% 6 4% (n 5 4) after 4 weeks of treatment (FiguresGlutamate transport is the primary mechanism for the
inactivation of synaptically released glutamate. Previous 1A and 1B). Sense oligonucleotide did not affect tissue
levels of the proteins (GLAST, 92% 6 2.3% [n 5 8];cell culture and cell fractionation studies have sug-
gested that both astroglia and neurons are capable of GLT-1, 103% 6 14% [n 5 4], EAAC1 120% 6 15% [n
5 4]) when compared to untreated control cultures. Thehigh affinity glutamate transport. Subsequently, three
glutamate transporters were clonedÐEAAC1 (Kanai and effect of antisense treatment was transporter subtype
specific; for example, antisense oligonucleotide toHediger, 1992), GLT-1 (Pines et al., 1992), and GLAST
(Storck et al., 1992) in rat and rabbitÐand the homolo- GLT-1 had no effect on the protein levels of GLAST
(95%) or EAAC1 (93%). The neurotoxic effect of the lossgous transporters have been identified in human brain
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Figure 1. In Vitro Effect of AntisenseOligonu-
cleotides to the Glutamate Transporters
GLT-1 and GLAST on Protein Expression and
Neuronal Survival
Antisense or sense oligonucleotides (5 mM)
to GLAST or GLT-1 were chronically added
to spinalcord organotypic cultures. At weekly
intervals, cultures were harvested and ho-
mogenates were analyzed for GLAST or
GLT-1 protein expression by immunoblot
analysis (A and B) followed by semiquantita-
tive densitometric evaluation (C and D). Lanes
were loaded with exactly equal amounts of
protein (15 mg). Choline acetyltransferase
(ChAT) activity, an enzymatic marker of motor
neurons, was measured in some homoge-
nates at weekly time points following sense
(squares) or antisense (circles) oligonucleo-
tide treatment (E and F). GYKI-52466, a non-
NMDA glutamate receptor antagonist, was
added to cultures (100 mM) along with GLT-1
antisense oligonucleotide (F, triangles) to de-
termine whether antisense-mediated motor
neuron toxicity was due to glutamate.
All time points in the figure represent the
mean 6 SEM of 2±7 determinations. Aster-
isks, p < .05 (compared with sense treatment
by Student's t test). There was no statistically
significant difference between sense-treated
cultures and untreated control cultures.
of glutamate transporter was evaluated by measuring in excitotoxicity, glutamate transporter subtype anti-
sense oligonucleotides were chronically administeredcholine acetyltransferase (ChAT) activity in culture ho-
mogenates. In this preparation, ChAT is selectively lo- intraventricularly, via miniosmotic pumps. Rats were
continuously treated for 7±10 days with intraventricularcalized to ventral motor neurons and can be used as a
reliable marker for motor neuron viability. The loss of antisense oligonucleotide to either GLAST, GLT-1, or
EAAC1. All sequences corresponded to untranslatedeither GLAST or GLT-1 protein was toxic to motor neu-
rons, as reflected by a progressive decline in spinal cord and translated amino terminal regions of GLAST, GLT-1,
or EAAC1 messenger RNA. Antisense, sense, or randomChAT activity (Figure 1E), similar to previous studies
using pharmacologic inhibition of glutamate transport- oligonucleotides were administered at a dose of 10
nmol/day. Animals were observed daily during adminis-ers (Rothstein et al., 1993). Although antisense to EAAC1
produced a 75% 6 11% (SEM; n 5 4) loss of protein, tration of the oligonucleotides. After 7±8 days, animals
were sacrificed and brains were rapidly frozen. In somethere was no associated motor neuron toxicity (data not
shown). In organotypic cultures, degeneration of motor cases, animals were perfused at sacrifice for detailed
histological evaluation of brain tissue.neurons following pharmacological inhibition of gluta-
mate transport can be selectively antagonized by non- Administration of either GLT-1 or GLAST antisense
oligonucleotide produced a progressive motor syn-NMDA glutamate receptor antagonists (Rothstein et al.,
1993; Rothstein and Kuncl, 1995). Similarly, the neuro- drome (Table 1); within 3 days animals began to exhibit
slowing of hindlimb movements, which progressed totoxicity associated with antisense oligonucleotide to
GLT-1 was completely prevented by the non-NMDA an- include unstable gait, mildly paretic hindlimbs, and dys-
tonic postures. By 7 days of treatment with antisensetagonist GYKI-52466 (Figure 1F), thus confirming the
specificity of the antisense effect. oligonucleotide to GLAST or GLT-1, most of the animals
were no longer able to ambulate because of paretic
hindlimbs. They continued to groom, eat, and appearedChronic Intraventricular Antisense Administration
To investigate more fully the role of each transporter alert, although weights were reduced by z28% 6 1.1%
compared with sense or random oligonucleotide±subtype in the clearance of extracellular glutamate and
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no alteration of either GLT-1 (96% of untreated control,Table 1. Behavioral Effects of Intraventricular Administration of
Antisense Oligonucleotides to Glutamate Transporter n 5 2) or GLAST (94% of untreated control, n 5 2)
Subtypes proteins. Thus, the biochemical and behavioral effects
of antisense oligonucleotides to glutamate transporterBehavior
Antisense subtypes appeared to be specific for the individual anti-
Treatment Motor Syndrome Seizures
sense sequences.
GLAST 17/17 1/17 The effect of antisense oligonucleotides on trans-
GLT-1 10/10 1/10 porter mRNA was evaluated by ribonuclease protection
EAAC1 7/14 12/14
assay. Seven days of GLAST antisense oligonucleotides
Data presented as number of animals with specific behavior per did not alter tissue GLAST mRNA (0.056 6 0.09; all
number treated. Motor syndrome refers to a progressive motor im- mRNA data are expressed as mean 6 SEM, arbitrary
pairment that typically begins with slowed hindlimb movements,
units representing the ratio of transporter mRNA toataxic unstable gait, culminating in hindlimb paresis.
b-actin mRNA by volumetric analysis; n 5 2±9 observa-
tions for each analysis) compared with control (0.053 6
treated animals.By contrast, administration of antisense 0.010). Similarly there was no effect of GLT-1 antisense
oligonucleotides to EAAC1 reliably produced epilepsy, oligonucleotides on GLT-1 mRNA (GLT-1 antisense 5
characterized initially by facial twitches and freezing 0.25 6 0.04; control 5 0.24 6 0.05) or EAAC1 antisense
behavior that began after 3±5 days of treatment. By oligonucleotides on EAAC1 mRNA (EAAC1 antisense 5
7 days, tonic forepaw extension and clonic seizures 0.032 6 0.004; control 5 0.036 6 0.006). The lack of
occurred (Table 1). Antisense oligonucleotide to EAAC1 effect of the antisense oligonucleotides on mRNA levels
also produced a motor syndrome in about one half of suggests that their biochemical actions are posttran-
the treated animals. However, motor impairment tended scriptional.
to be less severe compared with that obtained with Hippocampal glutamate transport and transporter
GLAST antisense oligonucleotide. Sense or random oli- proteins were also affected by intraventricular adminis-
gonucleotide for all three transporter subtype se- tration of antisense oligonucleotides. As shown in Figure
quences were without any behavioral effect up to 10 2E, individual antisense oligonucleotides inhibited the
days of treatment (n 5 6±10 per group). synthesis of their respective transporter proteins, and
After 7 days of intraventricular administration, anti- the magnitude of this effect was similar to that measured
sense oligonucleotide to GLAST produced an 84% 6 in the striatum. However, the contribution of each trans-
3.0% (n 5 12) loss of striatal GLAST protein by quantita- porter to total tissue glutamate transport was different
tive immunoblots (Figures 2A±2C). This was associated
in the striatum (Figure 2F), with a smaller role for GLAST
with a 35% 6 4.0% (n 5 7) loss of functional glutamate
(19%) and greater role for EAAC1 (43%). However, simi-transport (Figure 2D). Immunohistochemistry confirmed
lar to the striatum, astroglial glutamate transportersthat antisense oligonucleotides to GLAST diminished
were responsible for the greatest proportion (z60%) ofastroglial protein expression, whereas sense oligonucle-
hippocampal glutamate transport. The intraventricularotides had no effect (Figure 2B). There are a number of
administration of antisense oligonucleotides did not al-other important controls used to verify the specificity
ter transporter proteins or glutamate transport in moreof the antisense effects: first, treatment with antisense
distant structures including spinal cord and cerebellumoligonucleotides to GLAST did not affect striatal GLT-1
(data not shown).(95% 6 12% SEM of untreated control, n 5 4) or EAAC1
As an additional control for the increased formationprotein (93% 6 15% SEM of untreated control, n 5
4); second, missense oligonucleotides, containing the of intracellular RNA±oligonucleotideduplexes that could
same proportion of each nucleotide subtype of the anti- occur in astrocytes following the administration of
sense sequence were not neurotoxic and had no effect GLT-1 or GLAST antisense oligonucleotides, some ani-
on GLAST protein levels (n 5 2); and, third, the adminis- mals were treated with antisense to glial fibrillary acidic
tration of a mixture of GLAST sense and antisense oligo- protein (GFAP), an astroglial specific protein. Antisense
nucleotides (n 5 2) did not alter glutamate transport in oligonucleotide to GFAP (59-CAGAGGCGAGGTAGAA
striatal homogenates, had no effect on glutamate trans- CG-39), which decreased GFAP protein by 50% (n 5 2),
porters subtypes when examined by immunoblots, and had no behavioral effect, and did not affect glutamate
had no behavioral effect. transport (95% untreated control) or glutamate transport
Similarly, 7 days of antisense oligonucleotides to proteins (GLAST, 98%; GLT-1, 93%; and EAAC1, 102%
GLT-1 (n 5 9) produced a 58% 6 4.0% loss of striatal
of untreated control). Antisense to GFAP was also used
GLT-1 protein by immunoblot analysis (Figure 2C), but
in organotypic spinal cord cultures for up to 4 weeks atdid not affect the protein levels of GLAST (92% 6 12%
a concentration of 5 mM (n 5 4), and had no effect onof untreated control, n 5 4) or EAAC1 (109% 6 10% of
motor neuron survival.untreated control, n 5 10). The loss of GLT-1 protein
produced a 56% 6 4.8% loss of functional glutamate
transport in striatal homogenates (n 5 9; Figure 2D).
Effects of Antisense OligonucleotidesFinally, antisense oligonucleotides to EAAC1 delivered
on Extracellular Glutamateover 7 days intraventricularly (n 5 7), decreased striatal
Because glutamate transport is believed to maintain lowEAAC1 proteinby 78% 6 5.0% (Figure 2C) and produced
extracellular glutamate concentrations, we were inter-a 22% 6 3% loss of glutamate transport in striatal ho-
ested in determining if all, or selected transporter sub-mogenates (n 5 5). The effect of antisense oligonucleo-
tides to EAAC1 was specific, as immunoblots showed types, were responsible for this activity. As before,
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Figure 2. Analysis of Striatum and Hippocampus following In Vivo Administration of Oligonucleotides to Glutamate Transporter Subtypes
GLAST, GLT-1, and EAAC1
Oligonucleotides were delivered intraventricularly over 7 days (10 nmol/day). (A) Striatal tissue was collected and immunoblotted for glutamate
transporter subtypes (5) following treatment with antisense or sense oligonucleotide. For GLAST and EAAC1, each lane contains 15 mg protein
homogenates, while each lane for GLT-1 immunoblot has 5 mg striatal protein. Random oligonucleotides had no effect on transporter protein
levels (data not shown). (B) GLAST immunoreactivity in striatal tissue 7 days after chronic intraventricular infusions of GLAST sense or GLAST
antisense oligonucleotides compared with untreated control striatum. Immunostaining was performed on tissue ipsilateral to intraventricular
site. The reduction of neuropil GLAST immunoreactivity allows identification of individual GLAST-positive astrocytes (arrow). (C) Densitometric
analysis of immunoblots performed on GLAST, GLT-1, and EAAC1 in striatal tissue following sense or antisense oligonucleotide administration.
(D) Glutamate transport was measured in homogenates of striatal tissue following chronic treatment with an individual antisense or sense
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EAAC1 did not affect extracellular glutamate levels in
striatum. The rise in extracellular glutamate associated
with the loss of each transporter subtype (Figure 3A)
correlated significantly (p < .03) with the estimated per-
cent contribution of each transporter to total glutamate
transport (see Figure 2D).
Because GLAST and GLT-1 antisense treatments pro-
duce striatal neurotoxicity (see below), these elevations
could have reflected damage and release from neurons
rather than the steady-state rise in extracellular gluta-
mate due to the loss of transporter. To address that
possibility, extracellular asparagine was also monitored
during microdialysis. As shown in Figure 3B, there was
no increase in asparagine concentrations after 7 days
of GLAST antisense treatment. Thus, the changes in
extracellular glutamate likely reflect the loss of the trans-
porter protein.
Histological Evaluation
of Antisense Oligonucleotides
To address more directly whether sustained inhibition
of subtype specific transport can cause excitotoxic neu-
ronal damage in the whole animal, we administered
antisense oligonucleotides intraventricularly to either
GLAST, GLT-1, or EAAC1 by miniosmotic pumps. After
7 days, animals were sacrificed, and striatal and hippo-
campal tissue was examined by light and electron mi-
croscopy for evidence of cellular degradation.
The loss of either GLAST or GLT-1 protein, following
antisense treatment, produced neurotoxicity seen at
both the light and electron microscopic level (see Fig-
ures 5 and 6). When examined under low magnification,
there was no gross tissue necrosis (Figure 4) following
antisense treatment (Figures 4D±4F) compared with sev-
Figure 3. Microdialysis Determination of Extracellular Glutamate eral controls: untreated animals (Figure 4A), artificial ce-
and Asparagine Concentration following 7 Days of Intraventricular rebrospinal fluid (ACSF) control (Figure 4B), or sense
Oligonucleotides to Glutamate Transporter Subtypes oligonucleotide (GLT-1) control (Figure 4C). Ventricular
Microdialysis probes were placed in the striatum ipsilateral to intra- enlargement was typically seen on the side of intraven-
ventricular infusion cannulas in animals treated with antisense or
tricular cannulas (Figures 4B±4E), as well as occasionalsense oligonucleotides to GLAST, GLT-1, or EAAC1. Dialysate was
mild inflammation associated with cannula tracts (Fig-analyzed for both glutamate (A) and aspargine (B); 4±7 animals were
ures 4C±4F).studied for each oligonucleotide. Statistical significance of intraven-
tricular antisense treatment compared to sense treatment: asterisk, Closer inspection of striatal neurons confirmed the
p < .05; double asterisk, p < .01. ODN, oligonucleotide. overall preservation of neuronal populations in anti-
sense-treated tissue compared with sense-treated and
ACSF-treated tissue (Figures 5A±5C). However, striatalanimals were treatedwith senseor antisense oligonucle-
otides to individual transporter subtypes by chronic in- neurons in animals treated with antisense oligonucleo-
tides appeared enlarged and distorted following GLT-1traventricular infusion. After 7 days of treatment, microd-
ialysis probes were placed in the ipsilateral striatum to antisense (Figure 5C) and GLAST antisense (not shown)
treatment.sample extracellular amino acids. The loss of either glial
glutamate transporter, but not the neuronal transporter, To evaluate more completely the nature of these mor-
phological changes, semithin plastic sections and elec-was sufficient to produce a tonic rise in extracellular
glutamate levels. Glutamate concentrations in the mi- tron microscopy were performed. Semithin plastic sec-
tions revealed neurotoxic changes including frequentcrodialysate were markedly elevated almost 32-fold
(p < .01) after GLT-1 antisense oligonucleotide treat- cytoplasmic vacuoles and occasional degenerating
neurons (Figures 5D±5F). Neuronal cytotoxicity wasment, and about 13-fold (p < .05) after GLAST antisense
treatment (Figure 3A). Antisense oligonucleotides to most commonly seen following loss of either GLAST or
oligonucleotide as indicated. (E) Densitometric analysis of immunoblots performed on GLAST, GLT-1, and EAAC1 in hippocampus following
sense or antisense oligonucleotide administration. Each bar represents the mean 6 SEM of 5±12 determinations. (F) Glutamate transport was
measured in homogenates of hippocampal tissue following chronic treatment with an individual antisense orsense oligonucleotide as indicated.
Each bar represents the mean 6 SEM of 5±12 for (C) and (D), and 4±6 determinations for (E) and (F). Statistical significance of intraventricular
antisense treatment compared to sense treatment: double asterisks, p < .01. ODN, oligonucleotide.
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Figure 4. Coronal Sections of Rat Brain following Chronic Intraventricular Oligonucleotides
Animals were treated for 7 days with antisense oligonucleotides to GLAST (D), GLT-1 (E), or EAAC1 (F) compared to three different controls:
untreated (A), ACSF-treated (B), or sense (GLT-1; C) oligonucleotide-treated animals. At this low magnification of cresyl violet±stained sections,
there was gross tissue necrosis seen following these antisense treatments. Ventricular distortion was sometimes seen on the side of intraventric-
ular cannulas (arrowheads), along with cannula tract inflammation. Scale bar, 1.15 mm.
GLT-1 proteins (Table 2; Figures 5D±5F). Other cellular lysosomes. Occasional neurons appeared to be under-
going a complete disintegration. In many areas withinelements appeared unaffected by GLAST or GLT-1 anti-
sense treatment. Antisense EAAC1 treatment rarely pro- the striatum and hippocampus, there was widespread
swelling of dendrites, which sometimes contained ab-duced cellular changes at the light microscopic level of
observation in the striatum (Table 2), although occa- normal swollen mitochondria (Figures 6C, 6D, and 6H).
These ultrastructural changes are similar to those ob-sional vacuolated neurons were observed (Figure 5D) in
cortex along with vacuolization of hippocampal neuropil served in models of excitotoxicity (Olney, 1969; Olney
et al., 1983; Hajos et al., 1986). Animals treated with(Figure 5F). Sense treatment did not produce any evi-
dence of significant cytotoxicity (see Figures 4±6). EAAC1 antisense oligonucleotide had little ultrastruc-
tural changes in the striatum, although occasional en-Quantification of these changes in both striatum and
hippocampus, by examination of semithin plastic sec- larged dendrites contained vacuoles (Figure 6F). In the
hippocampus, there was more extensive dendritic swell-tions (Table 2), confirmed the increase in cytotoxicity
associated with antisense treatment for each of the glu- ing associated with the loss of EAAC1 (Figure 6H). There
was no evidence of cellular degeneration, by light micro-tamate transporters subtypes. The loss of GLAST or
GLT-1 protein appeared to produce more cytotoxicity scopic or electron microscopic observation, with sense
GLAST, GLT-1, or EAAC1 oligonucleotide adminis-than the loss of EAAC1 when examined in either striatum
or hippocampus. There was no significant cytotoxicity tration.
seen in either brain region following chronic sense or
ACSF treatment.
Electron microscopic evaluation of striatal and hippo- Discussion
campal neurons 7 days after continuous intraventricular
infusion of the antisense oligonucleotide to GLAST and Together, these in vitro and in vivo studies demonstrate
that the high affinity glutamate transporters GLAST andGLT-1 corroborated the light microscopic observations,
in that the most common cytological abnormalities in GLT-1 are important in maintaining low extracellular glu-
tamate concentrations and that elimination of either pro-neurons consisted of the formation of multiple vacuoles
of heterogenous size occupying the cytoplasmic com- tein produces a tonic increase in extracellular glutamate
resulting in neuronal degeneration. By antisense meth-partment (Figures 6C±6Eand 6I). The vacuoles appeared
to be formed from dilated endoplasmic reticulum, mito- odologies, it appears that the bulk of glutamate clear-
ance occurs through these astroglial transporters. Al-chondria (Figure 6D, inset), and lysosomal vacuoles con-
sisting of heterogenous material (Figure 6D). In some though they are not localized in the synaptic cleft
(Rothstein et al., 1994, 1995; Lehre et al., 1995), theirneurons, the Golgi apparatus appeared dilated. In other
affected neurons, there was an abundance of early de- function to maintain low extracellular glutamate must
be critical to preventing glutamate toxicity.generative changes that consisted of multiple lamellated
intracytoplasmic structures, some of them resembling The administration of the antisense oligonulceotides
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Figure 5. Intraventricular Administration of Antisense Oligonucleotides to Glutamate Transporter Subtypes Produced Cytotoxic Abnormalities
in Surrounding Cortex, Striatum, and Hippocampus
Calbindin D-28 immunoreactivity in the striatum after three treatments: ACSF (A), GLT-1 sense oligonulceotide (B), GLT-1 antisense oligonucleo-
tide (C). Neurons were grossly preserved in number following GLT-1 antisense treatment (C) compared to ACSF control (A) or GLT-1 sense-
treated (B) animals. However, neurons appeared vacuolated and enlarged after GLT-1 antisense. Closer inspection of semithin plastic sections
revealed antisense-induced cytotoxicity. (D) EAAC1 antisense treatment produced occasional neuronal cytotoxicity as reflected by numerous
cytoplasmic vacuoles (arrow) in a cortical pyramidal neuron. (E) GLT-1 antisense oligonucleotides produced vacuolar degeneration of many
striatal neurons (arrows). (F) EAAC1 antisense treatment produced extensive neuropil vacuolation in the hippocampus. Sections were stained
with toluidine blue. Scale bar, 50 mm (A±C); 15 mm (D and E); 25 mm (F).
appeared to produce selective knockout of individual antagonist GYKI-52466 also confirmed the specificity of
this method.transporter subtypes. Random and sense oligonucleo-
tide sequences had no effect on protein function or Interestingly, the loss of either glial transporter pro-
duced a progressive motor deficit that may be a conse-protein levels, thus confirming the selectivity of this
method. In vitro neuroprotection with the non-NMDA quence of neuronal cytotoxicity and/or degeneration.
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Table 2. Quantification of Abnormal Neurons following Administration of Antisense Oligonucleotides to Glutamate Transporter Subtypes
GLAST GLT-1 EAAC1
Artificial
Region CSF Control Antisense Sense Antisense Sense Antisense Sense
Striatum 0 4.8 6 0.44** 0 2.4 6 0.23** 0 0.8 6 0.23** 0
Hippocampus 0.1 6 0.04 3.0 6 0.25** 0 4.25 6 0.44** 0.12 6 0.04 1.1 6 0.15** 0
After 7 days of intraventricular administration, antisense oligonucleotides to all three glutamate transporters produced significant neurotoxicity
(e.g., vacuolization), while ACSF or sense oligonucleotides had no effect on neuronal morphology. Data are presented as the number of
abnormal neurons per high power (10003) microscopic field. Each value is the mean of 4±12 animals in which abnormal neurons were counted
in 10 random high power fields from semithin plastic sections of striatum or hippocampus (dentate gyrus). Double asterisk, p , .01 compared
to ACSF control.
Alternatively, the excessive extracellular glutamate, ob- suggest that inhibition of glutamate transport would ac-
tually result inpostsynaptic receptor desensitization andserved following the loss of the glial transporters, could
produce persistent synaptic depolarization and disrupt presynaptic inhibition of further glutamate release (Maki
et al., 1994; Tong and Jahr, 1994), thus moderating neu-neural circuitry.
Experiments on bulk isolated neurons and glia, and rotoxicity. Furthermore, the relative role of neuronal ver-
sus astroglial clearance of glutamate in excitotoxicity islater, on cultured neurons and astrocytes, have demon-
strated that these cellular populations are capable of not known. However, the antisense inhibition of individ-
ual transporter subtypes now provides histological evi-high affinity glutamate transport (Hertz, 1979). However,
the relative contribution of each population is unknown, dence that the loss of either astroglial glutamate trans-
porter is sufficient to cause excitoxicity, as reflected byand could only be inferred from analysis of transporter
kinetics (Hertz, 1979). There are no specific inhibitors of the vacuolar degeneration of neurons.
Surprisingly, EAAC1 antisense oligonucleotide treat-neuronal versus glial glutamate transport, nor are there
specific inhibitors that can distinguish molecular sub- ment caused neither drastic neurodegeneration nor ex-
tracellular glutamate elevation in the striatum. This maytypes. Although localization studies suggest differential
distributions of the transporter proteins, immunocyto- be because, under normal conditions, neuronal gluta-
mate transporters operate at or near equilibrium (Kanaichemical techniques are not adequate to assess the
functional contribution of transporter subtypes. By em- and Hediger, 1995; Kanai et al., 1995b). In neurons, intra-
cellular glutamate concentration is thought to be aroundploying antisense oligonucleotides, the contribution of
each transporter subtype to total clearance of extracel- 10 mM, whereas glutamate concentration in astroglia is
considerably lower (50 to several hundred micromolar).lular glutamate can now be inferred. These studies sug-
gest that the contribution of each glutamate transporter The lower glutamate concentration in glial cells may be
due to the rapid conversion of glutamate to glutamine,subtype to glutamate transport varies by brain region.
The glial glutamate transporters, GLT-1 and GLAST, pro- by glutamine synthetase that is present selectively in
astroglia (Riepe and Norenberg, 1977; Norenberg andvide the major contribution to high affinity glutamate
transportÐapproximately 80% in the striatum and 60% Martinez-Hernandez, 1979; Attwell et al., 1993; Pow and
Robinson, 1994). Therefore, neurons may not have ain the hippocampus (see Figure 2D)Ðwhereas EAAC1
appears to account for about 20% of striatal and 40% great capacity to take up extracellular glutamate,
whereas astroglia have a huge capacity to remove extra-of hippocampal glutamate transport. Thus, the three
known glutamate transporters account for almost all cellular glutamate. This hypothesis is supported by the
observation that EAAC1 contributes z20%±40% of glu-functional glutamate transport in the striatum and hippo-
campus. Additional support for this conclusion comes tamate transport.
The fact that neuronal glutamate transporters are al-from the microdialysis studies that demonstrated that
both the glial transporters, but not the neuronal trans- most at equilibrium suggests that the neuronal trans-
porters could run in the reverse direction more easily.porter, account for maintenance of low extracellular glu-
tamate levels. A fourth novel glutamate transporter has Reversal of glutamate transport has been proposed as a
mechanism of excitotoxicity under conditions of energybeen identified in humans, but it appears to berestricted
to the cerebellum (Fairman et al., 1995). Since these failure, as in cerebral ischemia (Nicholls and Attwell,
1990; Attwell et al., 1993; Kanai and Hediger, 1995; Kanaiexperiments were focused on the three high affinity glu-
tamate transporters known to be present in the striatum, et al., 1995b). Our experiments do not rule out the possi-
bility that EAAC1 could contribute to excitotoxicity asthey cannot rule out the contribution, albeit small, of
other uncloned glutamate transporters. a consequence of transport reversal. Loss of EAAC1
protein was sufficient to produce some behavioral ab-Glutamate transport has been postulated to be critical
in the maintenance of low extracellular glutamate to normalities, suggesting that disturbances of intrasynap-
tic glutamate by the loss of neuronal glutamate transportprotect against excitotoxic cell damage. Nonselective
transport blockers, used in vitro, have been shown to could alter some synaptic events, perhaps by persistent
depolarization or alteration in presynaptic transmitterraise extracellular glutamate, to alter postsynaptic po-
tentials (Isaacson and Nicoll, 1993; Sarantis et al., 1993; release. In addition, EAAC1 protein has been localized
to inhibitory GABAergic neurons, such as the cerebellarMennerick and Zorumski, 1994), and to result in neuro-
toxicity (Robinson et al., 1993; Rothstein et al., 1993; Purkinje cell (Rothstein et al., 1994). Since glutamate
is a precursor for GABA synthesis, EAAC1-mediatedBarks and Silverstein, 1994). However, some studies
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Figure 6. Qualitative Evaluation of Striatal and Hippocampal Neurotoxicity following Chronic Intraventricular Administration of Antisense
Oligonucleotides to GLAST, GLT-1, or EAAC1
(A) Control striatum from an animal receiving intraventricular ACSF demonstrating normal-appearing neurons and neuropil. (B) Chronic
administration of sense oligonucleotide to GLAST had no effect on striatal neurons or neuropil. Similarly, there was no effect of GLT-1 or
EAAC1 sense oligonucleotides (data not shown). Antisense oligonucleotides to GLAST produced marked pathological changes in striatal
neurons (C and D) including cytoplasmic vacuolization (arrow), massive dendritic dilatation (arrowhead), large intracytoplasmic multilamellated
structures (asterisks) and occasional dilated mitochondria (inset). (E) Antisense oligonucleotides to GLT-1 produced cytoarchitectural changes
identical to GLAST: cytoplasmic vacuolization (arrows) and dendritic swelling (arrowheads). (F) EAAC1 antisense oligonucleotide produced
little striatal pathology. Rarely, dendritic vacuoles were observed (arrowheads). (G) Control hippocampal neuropil of an animal following
intraventricular ACSF demonstrating normal-appearing synapses and dendrites (asterisks). Similarly, there was no effect of EAAC1, GLAST,
or GLT-1 sense oligonucleotides (data not shown). (H) Chronic treatment with EAAC1 antisense oligonucleotides resulted in marked dilatation
of dendrites (asterisks) and mitochondria (arrow), which contrasted with its mild cytotoxic effects in the striatum. Rarely, neurons with dilated
mitochondria and endoplasmic reticulum were seen following EAAC1 antisense oligonucleotide treatment (data not shown). (I) Antisense
oligonucleotides to GLAST produced pathological changes in hippocampal neurons similar to that seen in the striatum: lysosomes (asterisk),
vacuoles (arrow), and dilated endoplasmic reticulum. Scale bar, 2 mm (A±F); 1 mm (G±I).
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of antisense oligonucleotides included sense strands and ªrandomºglutamate transport could also have a functional role in
oligonucleotides in which the proportions of each adenine, thymi-GABA metabolism and neurotransmission.
dine, guanine, and cytosine nucleotide were identical to that ofAbnormal function of glutamate transporters has been
the antisense strand, but the sequence was randomly assigned.
implicated in acute and chronic neurological insults. A Sequences for the oligonucleotides used were as follows: sense
loss of glutamate transport in brain membranes has GLAST, 59-GAAAGATAAAATATGACAAAAAGCAAC-39 (correspond-
ing to nucleotides 212 to 15); antisense GLAST, 59-GTTGCTTTTTGTbeen found in the neurodegenerative disorder amyotro-
CATATTTTATCTTTC-39; sense GLT-1, 59-ATCAACCGAGGGTGCCAphic lateral sclerosis (Rothstein et al., 1992, 1995; Shaw
ACAATAT-39 (corresponding to nucleotides 6 to 29); antisenseet al., 1994), and more recent studies indicate that the
GLT-1, 59-ATATTGTTGGCACCCTCGGTTGAT-39; sense EAAC1,defect is specific for the GLT-1 protein (Rothstein et
59-GCTCGGGATGCGACTGGC-39 (corresponding to nucleotides 17
al., 1995). The antisense oligonucleotide experiments to 34); antisense EAAC1, 59-GCCAGTCGCATCCCGAGC-39. Addi-
suggest that the loss of either glial glutamate transporter tional random oligonucleotide sequences for the intraventricular ex-
periments included: GLAST, 59-TGTCGTTTTGTTATCTATATTCTTTcould account for, or contribute to, neuronal degenera-
CT-39; GLT-1, 59-AATTGTGTTAGCCCCCTCTGTTGA-39; EAAC1,tion in that disorder. The behavioral syndrome associ-
59-GCGGATCCGTACGCCCAG-39. Several other antisense se-ated with EAAC1, seizures and paresis, also suggests
quences for GLAST, EAAC1, and GLT-1 were investigated in prelimi-that dysfunction of this neuronal transporter could be
nary in vitro studies. Sequences were based on the rat GLT-1 (Pines
important in other neurological disorders such as epi- et al., 1992), rat GLAST (Storck et al., 1992), and rat EAAC1 (Kanai
lepsy. et al., 1995a). These oligonucleotides, which had lengths ranging
from 18- to 27-mer, had a variety of different start sites relative to the
gene's initiator codon. The efficacy of these antisense sequences atExperimental Procedures
inhibiting the synthesis of transport protein varied, some with no
effect on the protein (e.g., GLT-1 antisense, 59-CTCGGTTGATGCCAOrganotypic Cultures
TGGCGTGGGGAAC-39).Organotypic spinal cord cultures were prepared from 8-day-old rat
pup lumbar spinal cords, as described previously (Rothstein et al.,
1993). Culture media (50% MEM±HEPES [25 mM], 25% heat-inacti- Immunoblots
vated horse serum, and 25% Hanks' balanced salt solution [GIBCO] Animals were sacrificed by decapitation, and brains were rapidly
supplemented with D-glucose [25.6 mg/ml] and glutamine [2 mM], removed and placed on a chilled aluminum block (48C). Coronal
at a final pH of 7.2) was changed twice weekly. ChAT activity was sectionsof brain weresliced at 1±2 mm intervals from thecerebellum
measured as described previously (Rothstein et al., 1993). Phospho- to the olfactory bulbs. The striatum and hippocampus were
rothioate oligonucleotides were added with each biweekly culture microdissected from these slices and homogenized in Krebs buffer
media change for a final concentration of 5 mM. Other concentra- (pH 7.4). Immunoblots of the striatal or hippocampal homogenates
tions (up to 20 mM) were examined, and optimum results were ob- were prepared with affinity-purified polyclonal oligopeptide antibod-
tained with 5 mM. All oligonucleotides were reconstituted with cul- ies to GLAST, GLT-1, and EAAC1 as described previously (Rothstein
ture medium, then filtered before addition to cultures (0.2 mm). et al., 1994, 1995). For both GLT-1 and EAAC1, carboxy-terminal
Cultures were treated with oligonucleotides for up to four weeks in antibodies were used. For GLAST, both a carboxy-terminal antibody
culture. At weekly intervals, tissue was collected and homogenized. (Rothstein et al., 1994) and another monospecific amino-terminal
Aliquots of tissue homogenates were analyzed for ChAT activity or antibody (sequence: KSNGEEPRMGSRMGR) were employed. Both
immunoblotted for glutamate transporter subtypes (Rothstein et al., GLAST antisera produced identical immunoblots (J. Rothstein et al.,
1994, 1995). unpublished data). In some experiments, identical aliquots of striatal
tissue from animals treated with antisense oligonucleotides were
analyzed simultaneously for all three transporters by immunoblots,Intraventricular Antisense Administration
and immunoblot density was quantified by laser densitometry (Mo-Male Sprague±Dawley rats (250 g) were implanted with stainless
lecular Dynamics, CA).steel cannulas (stereo coordinates: 20.8 mm anterior±posterior;
21.5 mm lateral; approximately 24.8 mm dorsoventral) in the right
lateral ventricle. Correct placement of cannulas was confirmed in Immunohistochemistry
animals at the time of sacrifice. Phosphorothioate oligonucleotides The brains of 250 g male Sprague±Dawley rats (n 5 7) were prepared
were infused intraventricularly (1 ml/hr) using mini-osmotic pumps for immunocytochemical evaluation of GLT-1, GLAST, and EAAC1
(Alzet #2002, Alza Corp., Palo Alto, CA).Lyophilized oligonucleotides as described previously (Rothstein et al., 1994). Rats were perfused
were reconstituted in ACSF (0.14 mM NaCl, 3 mM K1, 1.25 mM intra-aortically with 4% paraformaldehyde in phosphate-buffered
Ca21, 0.48 mM HPO4, 21 mM HCO3, 3.4 mM glucose, 2.2 mM urea, saline. Brains were removed, blocked, and postfixed (1 hr, 48C), then
pH 7.4 [Merlis, 1940]) at a concentration of 2.5 mg/ml. Freshly recon- cryoprotected (overnight, 48C) in 20% glycerol, phosphate-buffered
stituted oligonucleotides were dialyzed [SpectraPor cellulose ester, saline. Coronal sections (40 mm) were cut on a sliding microtome
MW cutoff 2000 (Thomas Scientific)] overnight in 2 l ACSF (48C), and were transferred to cold Tris-buffered saline (TBS; pH 7.2). For
then filtered (0.22 mm) prior to use. Oligonucleotides were loaded some experiments, coronal sections were dehydrated with ethanol
into mini-osmotic pumps, then connected to intraventricular cannu- and stained with cresyl violet. For immunohistochemical evaluation,
las by polyethylene tubing, and placed subcutaneously. In some sections were pre-incubated (1 hr) with 4% normal goat serum di-
experiments, rats (n 5 2) were treated intraventricularly with a mix- luted in 0.1% Triton X-100 (TX)/TBS and were then incubated (48
ture of sense and antisense oligonucleotides for 7 days. Prior to hr, 48C) in the affinity-purified transporter antibody, at a concentra-
administration, oligonucleotides (500 ng GLAST sense oligonucleo- tion of 0.2 mg/ml for GLAST, 0.06 mg/ml for EAAC1, and 0.17 mg/ml
tide and 100 ng antisense oligonucleotide dissolved in ACSF) were for GLT-1 of IgG per milliliter in 0.1% TX, 2% normal goat serum,
dialyzed, filtered, then mixed overnight at room temperature. TBS. For some experiments, tissue was stained with antibody to
calbindin D-28 (Sigma Immunochemicals, St. Louis) at 1:2000. Fol-
lowing primary antibody incubation, sections were rinsed (30 min)Antisense Oligonucleotides
Initial studies indicated that consistent inhibition of glutamate trans- in TBS, incubated (1 hr) with goat anti-rabbit (Cappel) diluted 1:200
in TBS with 2% normal goat serum and 0.1% TX. After rinsing inport was obtained with phosphorothioate derivatives. Phosphodies-
ter oligonucleotides were used owing to the rapid degradation of TBS, the sections were incubated (1 hr) in rabbit peroxidase±
antiperoxidase complex (Sternberger Monoclonals, Baltimore, MD)unmodified oligonucleotides (Whitesell et al., 1993; Wagner, 1994).
In all cases, the sequences chosen were novel and unrelated to any diluted 1:300 in TBS with 2% normal goat serum. For calbindin
D-28 staining, tissue was incubated with goat-anti-mouse 1:200,other nucleotide sequence in GenBank. Sequences for the sense
and antisense oligonucleotides of GLAST, GLT-1, and EAAC1 were followed by incubation mouse peroxidase±antiperoxidase complex
(Sternberger Monoclonals, Baltimore, MD) diluted 1:200. After theidentical in all experimental paradigms used. Controls for the effects
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final incubation, sections were rinsed (30 min) in TBS and developed coordinates: 21 mm anterior±posterior; 23.0 mm lateral; approxi-
mately 23.8 mm dorsoventral). Dialyzates were collected automati-using a standard diaminobenzidine reaction.
cally into 200 ml glass minivials, maintained at 48C, at 30 min inter-
vals, using a flow rate of 2 ml/min. Amino acid analysis of dialyzatesElectron Microscopy
(20 ml) was performedby reverse phasehigh pressure liquid chroma-The brains of 250 g male Sprague±Dawley rats were prepared for
tography using precolumn derivatization and fluorescence detectionboth light and electron microscopic evaluation as described pre-
for glutamate and asparagine (Shimada et al., 1993). In vitro probeviously (Rothstein et al., 1994). The striatum or hippocampus from
recovery was determined after the in vivo experiment by placingat least 4 animals for each oligonucleotide treatment group was
the probe in a plastic vial (2 ml) containing a known concentrationexamined by electron microscopy. Rats were perfused intra-aor-
of amino acids. The brainextracellular fluidconcentration was calcu-tically with 4% paraformaldehyde/0.1% glutaraldehyde/15% satu-
lated by dividing the in vivo dialyzate concentration by the in vitrorated picric acid/2% acrolein or with 4% paraformaldehyde alone,
recovery.both prepared in phosphate-buffered saline. Brains were removed,
blocked, and postfixed (1 hr, 48C). Brains for light microscopy were
Statistical Analysiscryoprotected (overnight, 48C) in 20% glycerol, phosphate-buffered
Analysis of changes in treatment groups was performed using Stu-saline. Brains prepared for electron microscopy were rinsed in cold
dent's t test.phosphate-bufferedsaline. Coronal or sagittal sections (40 mm)were
cut on a sliding microtome or Vibratome and were transferred to
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